Cite
MLA Citation
Philippe Merle et al.. “Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.” Lancet gastroenterology and hepatology, vol. 4, 2019, pp. 454–465. http://access.bl.uk/ark:/81055/vdc_100084767978.0x000004